关键词: 前-C区突变, 基本C区启动子区突变, 拉米呋啶

Abstract: Objective To investigate of the mutations in the PreC G1896A and in the basic core promoter (BCP) A1762T and G1764A as well as the effects of YMDD mutants on Lamivudine therapy against chronic hepatitis B virus (HBV) infection.Methods Serum samples were obtained before, during and after therapy. Parts of the HBV polymerase gene flanking the YMDD motif and the PreC/BCP region were sequenced after polymerase chain reaction (PCR) amplification. Results ①There were no significant differences of the mutations in PreC G1896A and BCP A1762T,G1764A between patients with viral breakthrough (VBT) and without VBT, as well as patients with seroconversion and without seroconversion (P>0.05).②There were significant difference of mutations in G1896A between patients with and without YMDD mutants (P<0.05), and the mutation detection rate (9%) in patients with YMDD mutants was lower. ③There was significant difference of YMDD mutants between patients with VBT and without VBT (P<0.05). Conclusion The mutations in PreC G1896A and BCP A1762T, G1764A have not effects on VBT and seroconversion following Lamivudine therapy,and G1896A may reduce the appearance of YMDD. The YMDD mutants may be one of the factors that aggravate the damage of hepatocytes during the relapse.

Key words: PreC mutation, basic core promoter mutation, Lamivudine